Photo from archive.org
To inform patients and their carers about both the probability of reducing glycated haemoglobin (HbA1c) to clinically desirable levels and the sustainability of such control over 2 years with major… Click to show full abstract
To inform patients and their carers about both the probability of reducing glycated haemoglobin (HbA1c) to clinically desirable levels and the sustainability of such control over 2 years with major second‐line antidiabetic therapies, in individual risk scenarios, with and without third‐line intensification.
Keywords:
line antidiabetic;
line;
long term;
antidiabetic therapies;
sustainability;
second line
Journal Title: Diabetes
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Diabetes
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!